Articles Referencing MAA
Gilead's Sofosbuvir under European Review - Analyst Blog
5/22/2013, 4:27 pm from Zacks.com in Investing, Business, Stocks
Gilead Sciences Inc. ( GILD ) recently
announced that its Marketing Authorisation Application (MAA) for
HCV candidate sofosbuvir (formerly GS-7977), submitted to the
European Medicines... Read >>
Bayer's Xofigo Cleared in the US - Analyst Blog
5/16/2013, 6:30 pm from Zacks.com in Investing, Business, Stocks
Bayer 's ( BAYRY ) HealthCare
segment recently received encouraging news as the US Food and Drug
Administration (FDA) approved its oncology drug Xofigo (radium 223
dichloride). Xofigo was... Read >>
ARNA Sheds Light on Belviq Launch - Analyst Blog
5/9/2013, 4:24 pm from Zacks.com in Investing, Business, Stocks
Arena Pharmaceuticals Inc. ( ARNA ) recently
announced that the US Drug Enforcement Administration (DEA) has
assigned its obesity drug Belviq into Schedule IV of the Controlled
Substances... Read >>
Ariad Posts Wider Y/Y Loss - Analyst Blog
5/8/2013, 10:23 am from Zacks.com in Investing, Business, Stocks
Ariad Pharmaceuticals, Inc. ( ARIA ) reported first
quarter loss of 36 cents per share, wider than the year-ago loss of
25 cents per share but narrower than the Zacks Consensus Estimate
of... Read >>
Wider-than-Expected Loss at Endocyte - Analyst Blog
5/6/2013, 2:18 pm from Zacks.com in Investing, Business, Stocks
Endocyte, Inc. ( ECYT ) reported first
quarter 2013 net loss per share of 11 cents, wider than the Zacks
Consensus Estimate of a loss of 5 cents but narrower than the
year-ago loss... Read >>
Arena Pharma Narrows Loss - Analyst Blog
5/6/2013, 11:21 am from Zacks.com in Investing, Business, Stocks
Arena Pharmaceuticals Inc. 's ( ARNA ) loss (excluding
special items) of 10 cents per share in the first quarter of 2013
was narrower than the year-ago loss of 15 cents per share. The
Zacks... Read >>
Loss at Aegerion Narrower Than Expected - Analyst Blog
5/3/2013, 4:29 pm from Zacks.com in Investing, Business, Stocks
Aegerion Pharmaceuticals, Inc. ( AEGR ) reported first
quarter 2013 net loss per share of 64 cents, narrower than the
Zacks Consensus Estimate of a loss of 72 cents, but wider than... Read >>
Positive CHMP Opinion for Avanir - Analyst Blog
5/1/2013, 10:48 am from Zacks.com in Investing, Business, Stocks
Avanir Pharmaceuticals, Inc. ( AVNR ) recently
received a positive opinion from the Committee for Medicinal
Products for Human Use (CHMP) for Nuedexta. Nuedexta is under review in the EU... Read >>
BioMarin Widens Loss, Maintains View - Analyst Blog
4/29/2013, 11:50 am from Zacks.com in Investing, Business, Stocks
BioMarin Pharmaceutical Inc. 's ( BMRN ) first quarter
2013 loss of 31 cents per share was wider than the Zacks Consensus
Estimate of a loss of 28 cents per share and the year-ago loss... Read >>
SNY's Vaxigrip Filing Accepted in EU - Analyst Blog
4/11/2013, 7:11 pm from Zacks.com in Investing, Business, Stocks
Sanofi ( SNY ) recently
announced that a decentralized marketing authorization application
(MAA) for its quadrivalent flu vaccine, Vaxigrip, has been accepted
for review in the EU.
The... Read >>
ARNA/Eisai's Belviq Filed in Mexico - Analyst Blog
4/3/2013, 4:19 pm from Zacks.com in Investing, Business, Stocks
Arena Pharmaceuticals, Inc. ( ARNA ) recently
announced that Eisai Laboratories S. de R.L. de C.V, a subsidiary
of Eisai Inc., has submitted a marketing authorization application
(MAA) for... Read >>
Vivus Opts for Royalty Financing - Analyst Blog
4/2/2013, 7:21 pm from Zacks.com in Investing, Business, Stocks
Vivus, Inc. ( VVUS ) recently
announced that it has entered into an agreement with a Pharmakon
Advisors managed investment fund for a $110 million non-equity
financing. Vivus will initially... Read >>
Lilly Progresses with Empagliflozin - Analyst Blog
4/1/2013, 6:07 pm from Zacks.com in Investing, Business, Stocks
Eli Lilly ( LLY ) and Boehringer
Ingelheim recently submitted a New Drug Application (NDA) for their
type II diabetes candidate, empagliflozin, in the US. Earlier this
year, Eli Lilly... Read >>
Astellas' Acofide Approved in Japan - Analyst Blog
3/27/2013, 3:27 pm from Zacks.com in Investing, Business, Stocks
Astellas Pharma, Inc. ( ALPMY ) and Zeria
Pharmaceutical Co., Ltd. recently announced that it received
approval from Japan's Ministry of Health, Labour and Welfare (MHLW)
for Acofide for... Read >>
Gilead's Stribild Backed by CHMP - Analyst Blog
3/25/2013, 7:27 pm from Zacks.com in Investing, Business, Stocks
Gilead Sciences, Inc. ( GILD ) announced that
the European Medicines Agency's (EMA) Committee for Medicinal
Products for Human Use (CHMP) recently rendered a positive opinion
on its HIV... Read >>